SynthesisInternational journal of molecular sciences2026
MicroRNA Expression Profiles as Biomarkers of Response to Disease-Modifying Therapies in Multiple Sclerosis: A Systematic Review.
Synthesis in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although microRNAs (miRNAs) are an active area of research in multiple sclerosis (MS) and have been proposed as potential biomarkers of treatment response, the evidence remains difficult to interpret. This systematic review examines the relationship between miRNA expression and response to disease-modifying therapies (DMTs) in adults with MS. The PubMed/MEDLINE and Web of Science databases were systematically searched from inception to 11 February 2026. Fifteen studies that compared miRNA expression between responders and non-responders or assessed changes in miRNA expression after DMT initiation were synthesized narratively by treatment group and outcome, in accordance with the 2020 PRISMA guidelines. After considering study design, treatment response definitions, and miRNA analytical methods, miR-548a-3p in fingolimod-treated patients and miR-223-3p, miR-23a/b-3p, and miR-27a/b-3p in dimethyl fumarate (DMF)-treated patients appeared the most promising miRNAs investigated; however, each was assessed in a single study and has not yet been validated in independent external cohorts. However, they were notable because they had been evaluated in clinically relevant settings: miR-548a-3p in relation to no evidence of disease activity-3 and receiver operating characteristic-based discrimination, and the DMF-associated miRNAs through baseline expression levels and early fold-change analyses. Although miR-23a-3p, miR-26a-5p, miR-146a-5p, miR-155, miR-34a-5p, miR-223-3p, miR-660-5p, and miR-326 had been reported in more than one study, most were investigated in different DMT or outcome contexts. Therefore, the existing literature correlating miRNA expression levels with treatment response provides valuable but limited and heterogeneous evidence. Thus, miRNAs should currently be considered exploratory biomarkers and require further independent validation before their use in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.